Cardiac Arrest, Unexplained with CC DRG Reimbursement Guide

DRG 297 pertains to inpatient admissions for unexplained cardiac arrest with a Complication or Comorbidity, encompassing high-acuity resuscitation and diagnostic care. Classification into this Diagnosis-Related Group matters for Medicare inpatient reimbursement because documented complications and resource intensity determine payment under the inpatient prospective payment system.

DRG 297 Overview

DRG 297 covers inpatient stays for patients admitted with cardiac arrest of unexplained origin when a Complication or Comorbidity is present. This Diagnosis-Related Group captures high-acuity cardiac emergencies that often require intensive monitoring, advanced life support, and diagnostic workup to determine cause. It matters for Medicare payment because acuity and associated complications drive resource use and reimbursement under the inpatient prospective payment system. Accurate coding of the arrest and any Complication or Comorbidity directly affects classification into this Diagnosis-Related Group and resulting payment.

Acute resuscitation and postarrest neuroprotection trials: randomized or observational studies testing strategies applied during the immediate cardiac arrest event and early inpatient period (for example, optimization of advanced cardiac life support protocols, timing and parameters of targeted temperature management, and bundled postarrest hemodynamic and ventilation strategies). These studies enroll adult inpatients who experience unexplained cardiac arrest and survive to hospital admission, often stratified by initial rhythm and presence of shock; the objective is to reduce early mortality and limit anoxic brain injury. Results are directly relevant to clinicians managing critical care in this DRG and to payers because improved acute protocols can shorten ICU stays, reduce complications, and alter resource utilization.
Diagnostic pathway and etiology-detection studies: prospective cohort studies evaluating multimodal testing algorithms (cardiac imaging, coronary angiography timing, extended cardiac rhythm monitoring, cardiac MRI, and selected genetic testing) to determine causes of unexplained cardiac arrest and appropriate secondary prevention. These studies target survivors of unexplained arrest without an immediately apparent cause, aiming to increase diagnostic yield for ischemic, structural, or arrhythmic etiologies and guide decisions about revascularization, implantable devices, or medical therapy. Accurate etiologic classification affects subsequent interventions and long-term costs; payers and hospitals benefit from evidence that optimizes use of high-cost diagnostics while avoiding unnecessary procedures.
Post-discharge outcomes, rehabilitation, and secondary prevention trials: observational studies and interventional trials examining inpatient-to-outpatient transitions, neurorehabilitation strategies, medication adherence programs, and device therapy uptake (for example, enrollment in structured cardiac rehab or remote rhythm monitoring after discharge). These studies follow patients who survived unexplained cardiac arrest through recovery and readmission windows to measure functional outcomes, quality of life, recurrent arrest or readmission rates, and cost-effectiveness of outpatient management approaches. Findings inform providers and payers about interventions that reduce long-term morbidity, readmissions, and total cost of care for this high-risk DRG population.

Acute resuscitation and postarrest neuroprotection trials: randomized or observational studies testing strategies applied during the immediate cardiac arrest event and early inpatient period (for example, optimization of advanced cardiac life support protocols, timing and parameters of targeted temperature management, and bundled postarrest hemodynamic and ventilation strategies). These studies enroll adult inpatients who experience unexplained cardiac arrest and survive to hospital admission, often stratified by initial rhythm and presence of shock; the objective is to reduce early mortality and limit anoxic brain injury. Results are directly relevant to clinicians managing critical care in this DRG and to payers because improved acute protocols can shorten ICU stays, reduce complications, and alter resource utilization.
Diagnostic pathway and etiology-detection studies: prospective cohort studies evaluating multimodal testing algorithms (cardiac imaging, coronary angiography timing, extended cardiac rhythm monitoring, cardiac MRI, and selected genetic testing) to determine causes of unexplained cardiac arrest and appropriate secondary prevention. These studies target survivors of unexplained arrest without an immediately apparent cause, aiming to increase diagnostic yield for ischemic, structural, or arrhythmic etiologies and guide decisions about revascularization, implantable devices, or medical therapy. Accurate etiologic classification affects subsequent interventions and long-term costs; payers and hospitals benefit from evidence that optimizes use of high-cost diagnostics while avoiding unnecessary procedures.
Post-discharge outcomes, rehabilitation, and secondary prevention trials: observational studies and interventional trials examining inpatient-to-outpatient transitions, neurorehabilitation strategies, medication adherence programs, and device therapy uptake (for example, enrollment in structured cardiac rehab or remote rhythm monitoring after discharge). These studies follow patients who survived unexplained cardiac arrest through recovery and readmission windows to measure functional outcomes, quality of life, recurrent arrest or readmission rates, and cost-effectiveness of outpatient management approaches. Findings inform providers and payers about interventions that reduce long-term morbidity, readmissions, and total cost of care for this high-risk DRG population.

OpenPayer

Summary & Overview

Cardiac Arrest, Unexplained with CC: Inpatient Reimbursement Overview

DRG 297 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes